Loading
A phase 2 trial of RAD101 (18F-FPIA) in brain and spinal cord tumours, run by Radiopharm Theranostics, Ltd, active and no longer recruiting.
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases is a phase 2 interventional study registered as NCT06777433 by Radiopharm Theranostics, Ltd, with 30 participants enrolled, started 2024-12-13 and due to reach its primary completion in 2026-04-23. Interventions recorded: RAD101 (18F-FPIA).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Medpace, Radiopharm Theranostics and the tag pipeline.
Shares Medpace and the tag pipeline.
Shares Medpace and the tag pipeline.
Shares Radiopharm Theranostics and the tag pipeline.
Shares Medpace and the tag pipeline.
Shares Brain metastases (secondary brain tumours), Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Brain metastases (secondary brain tumours), Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Brain metastases (secondary brain tumours), Brain and spinal cord tumours (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/